PACB MonthlyMy game plan for 2025. Monthly wedge breakout, cup+handle formations on daily/weekly to resolve near +30 EOY
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.14 USD
−309.85 M USD
154.01 M USD
262.18 M
About Pacific Biosciences of California, Inc.
Sector
Industry
CEO
Christian O. Henry
Website
Headquarters
Menlo Park
Founded
2000
FIGI
BBG000QKXH20
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Short Term Stock Watch - 07Dec2025 - $PACBTime for a breakout?
Nice potential short term swing trade.
Note: This is not a recommendation or investment advice, just a stock to watch. Do your own research before getting into a trade.
Pacific Biosciences of California, Inc. (NASDAQ: PACB) 1. Company Overview
About: Pacific Biosciences, also known as PacBio, is a life sciences technology firm specializing in sequencing solutions for complex genomic applications. Its core products include HiFi long-read sequencing and Single Molecule, Real-Time (SMRT) sequencing technologies. These pr
Pacb LongTarget the apex of the LOG chart pattern, been getting a lot of bullish block trade activity on my end.
PACB - +160% upside with a 1:3.5 RRSet-up nicely for a breakout.
Seems like its consolidating and due a move up higher on breakout.
I expect the move to be a 2x at least to $4-5.
BUT not yet broken out and I am waiting on confirmation of momentum.
Pacific Biosciences of California, Inc. - positive divergenceOn the 5 day chart price action has corrected 90% since closing the previous idea (below) on June 21st 2023 after a 200% rally. A number of reasons now exist to consider a new long position now that the short is closed.
1) RSI resistance breakout and backtest confirmation.
2) Strong regular bullis
PACB - Flushed Out - Potential 20 bagger hereOk so we are all looking for that next 20 bagger right? Biotechs and moreover disrupter Biotechs are so hated right now they are IMO a deal.
Now not all Biotechs will be big winners, some will go to zero, but if the potential to go to zero is there, it is best to buy near zero ;)......
So I am g
PACB - LONGAt the upcoming TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference, PacBio is expected to present corporate updates, including recent achievements and product advancements, financial performance, and strategic outlook. The company may also discuss indus
PACB WeeklyHere's a little less optimistic outlook than the PACB Monthly chart. Spending more time near the lower trend line before moving higher towards upper trend line. Either way, all roads eventually lead to Rome.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
PACB5630687
Pacific Biosciences of California, Inc. 1.375% 15-DEC-2030Yield to maturity
—
Maturity date
Dec 15, 2030
PACB5949325
Pacific Biosciences of California, Inc. 1.5% 15-AUG-2029Yield to maturity
—
Maturity date
Aug 15, 2029
See all PACB bonds
Related stocks
Frequently Asked Questions
The current price of PACB is 1.17 USD — it has increased by 3.85% in the past 24 hours. Watch Pacific Biosciences of California, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Pacific Biosciences of California, Inc. stocks are traded under the ticker PACB.
PACB stock has fallen by −4.33% compared to the previous week, the month change is a −8.65% fall, over the last year Pacific Biosciences of California, Inc. has showed a −25.00% decrease.
We've gathered analysts' opinions on Pacific Biosciences of California, Inc. future price: according to them, PACB price has a max estimate of 3.50 USD and a min estimate of 1.00 USD. Watch PACB chart and read a more detailed Pacific Biosciences of California, Inc. stock forecast: see what analysts think of Pacific Biosciences of California, Inc. and suggest that you do with its stocks.
PACB reached its all-time high on Feb 11, 2021 with the price of 53.69 USD, and its all-time low was 1.06 USD and was reached on Nov 15, 2012. View more price dynamics on PACB chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PACB stock is 8.70% volatile and has beta coefficient of 0.49. Track Pacific Biosciences of California, Inc. stock price on the chart and check out the list of the most volatile stocks — is Pacific Biosciences of California, Inc. there?
Today Pacific Biosciences of California, Inc. has the market capitalization of 348.49 M, it has decreased by −13.97% over the last week.
Yes, you can track Pacific Biosciences of California, Inc. financials in yearly and quarterly reports right on TradingView.
Pacific Biosciences of California, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
PACB earnings for the last quarter are 0.01 USD per share, whereas the estimation was −0.19 USD resulting in a 105.26% surprise. The estimated earnings for the next quarter are −0.19 USD per share. See more details about Pacific Biosciences of California, Inc. earnings.
Pacific Biosciences of California, Inc. revenue for the last quarter amounts to 39.22 M USD, despite the estimated figure of 40.10 M USD. In the next quarter, revenue is expected to reach 35.44 M USD.
PACB net income for the last quarter is 3.57 M USD, while the quarter before that showed −60.73 M USD of net income which accounts for 105.88% change. Track more Pacific Biosciences of California, Inc. financial stats to get the full picture.
No, PACB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 575 employees. See our rating of the largest employees — is Pacific Biosciences of California, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pacific Biosciences of California, Inc. EBITDA is −212.09 M USD, and current EBITDA margin is −137.72%. See more stats in Pacific Biosciences of California, Inc. financial statements.
Like other stocks, PACB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pacific Biosciences of California, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pacific Biosciences of California, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pacific Biosciences of California, Inc. stock shows the sell signal. See more of Pacific Biosciences of California, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.